Joaquín Martínez-Arrarás, MD, FACC, FSCAI

Doctor Joaquin Martinez Arraras
Logo Amarillo Heart Institute



Amarillo Heart Institute

Founder Partner


Texas Cardiovascular Center (TCC)

Founder & Partner


  • Universidad de Navarra, Pamplona, Spain.


  • Internal Medicine, Interfaith Medical Center, Brooklyn, NY.


  • Research fellowship, Children’s Exercise Physiology. Universidad de Navarra, Pamplona, Spain.
  • Clinical Cardiology, Saint Raphael’s, New Haven, CT.
  • Interventional Cardiology, Saint Raphael’s, New Haven, CT.


  • U.S. Patent 9095684-B2. Bidirectional introducer catheter. August 2015. 

Partner & Founder

  • Amarillo Heart Group. Amarillo, TX.
  • Amarillo Heart Research Center. Amarillo, TX.

Board Certification (s)

  • Fellow of society of Cardiovascular Angiography & interventions, FSCAI.
  • Fellow of the American college of Cardiology, FACC.
  • American Board of Internal Medicine, ABIM.
  • American Board of Cardiovascular Disease, ABCD.
  • American Board of Interventional Cardiology, ABIC.


  • Director of Congestive Heart Failure Services at Amarillo Heart Group.
  • Texas Cardiovascular Center. Medical Director.
  • Baptist St. Anthony Hospital System Cardiology Section Committee member.
  • NWTH President of Medical Stuff.

2008, 2009, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023

Publications & Abstracts

Molecular Cardiology: Some  Answers to Age-Old Questions: Joaquin Martinez-Arraras, M.D. Panhandle Health, Spring 2003, Volume13, Number 2, Page 29.

Cardiovascular Disease in Women, Risk and Controversy: Joaquin Martinez-Arraras, M.D. and Theresa Salicco, R.N. Panhandle Health, Summer 1993, Volume 3, Number 4.

Procedure- and Lead-Related Complications: Insights from the WRAP-IT Study: HRS Abstract- 2020: Joaquin Martinez-Arraras, MD; Suneet Mittal, MD; Bruce Wilkoff, MD; Jeanne Poole, MD; Charles Kennergren, MD PhD; David J. Wright, MD; Bret Berman, MD; David Riggio, MD; Darius Sholevar, MD; Jean Moubarak, MD; Robert Schaller, MD; John Love, MD; Robert A. Picket, MD; Francois Phillipon, MD; Zayd Eldadah, MD; Jeff Lande, PhD; Dan Lexcen, PhD; Khaldoun Tarakji, MD MPH: PlasmaBlade Electrocautery Reduces.

Antibiotic Envelope Infection Prevention (WRAP-IT) trial: Long term follow-up: Joaquin Martinez-Arraras (WRAP-IT Investigators): Mittal S, Wilkoff BL, Kennergren C, et al. The World-wide Randomized [published online ahead of print, 2020 Feb 19]. Heart Rhythm. 2020;S1547-5271(20)30113-2. doi:10.1016/j.hrthm.2020.02.011

Prevent Cardiac Implantable Device Infection. N Engl J Med: Joaquin Martinez-Arraras, MD (WRAP-IT Investigators): Tarakji KG, Mittal S, Kennergren C, et al. Antibacterial Envelope to 2019;380(20):1895-1905. doi:10.1056/NEJMoa1901111

Principal Investigator

  • Broadway: (May 2022 to present) Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY): A  Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of  10 mg Obicetrapib in Participants With Underlying HeFH and/or Atherosclerotic  Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled by Their Lipid Modifying Therapies
  • ORION 8: (Started 7/5/2019 to present). A long term extension trial of the Phase II lipid-lowering trials to assess the effect of long  term dosing of Inclisiran given as subcutaneous injections in subjects with high  cardiovascular risk and elevated LDL-C (ORION-8)
  • ORION 10: (Started 12/2017 to Present). A placebo-controlled, double-blind, randomized trial to evaluate the effect of 300 mg of  Inclisiran sodium given as subcutaneous injections in subjects with atherosclerotic  cardiovascular disease (ASCVD) and elevated low-density lipoprotein cholesterol (LDL c). 
  • AMG 423-(Galactic) – (Started 2/22/2017 to Present). A Double-Blind, Randomized, Placebo-controlled, Multicenter Study to Assess the  Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with  Chronic Heart Failure With Reduced Ejection Fraction.
  • ORION I, ORION III -(Started 4/14/2016 to Present). A placebo-controlled, double-blind, randomized trial to compare the effect of different doses of ALN-PCSSC given as single or multiple subcutaneous injections in subjects with high cardiovascular risk and elevated LDL-C.
  • ABSORB IV- ABSORB IV RANDOMIZED CONTROLLED TRIAL– (2014 to Present) A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular  Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions.
  • ABSORB III Randomized Control Trial– (2013 to March 2019). A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular  Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions.
  • Miracle EF– (7/2013 to 4/2014). A prospective, randomized, controlled, double-blinded, global multi-center, Cardiac  Resynchronization Therapy (CRT) in Heart Failure (HF) clinical study. The purpose of  this study is to evaluate market released CRT pacemaker (CRT-P) devices in  symptomatic HF patients with less severe left ventricular systolic dysfunction, specifically  patients with reduced left ventricular ejection fraction (LVEF) in the range of 36% to  50%. 
  • CHOICE- Closed. Carotid Stenting For High Surgical-Risk Patients’ Evaluating Outcomes Through The  Collection of Clinical Evidence. 
  • Hercules- Closed: A Prospective, non-randomized, multi-center, single-arm clinical trial to assess the safety and efficacy of the RX HERCULINK® ELITE™ renal stent system for the treatment of subobtimal post procedural Percutaneous Transluminal Angioplasty (PTA) in Atherectomic de novo or restenotic renal artery stenoses in patinet with uncontrolled hypertension. 
  • Moxie: An Exploratory Double-Blind, Placebo Controlled, Randomized, 12-Week Oral Dose  Study to Evaluate the Effects of MK-0736 on Atherosclerotic Disease Biomarkers in  Lower Extremity Plaque Excised From Patients With Peripheral Arterial Disease. 
  • Protect – Closed: A multicenter, randomized, double-blind, placebo-controlled study of the effects of KW 3902 Injectable Emulsion on heart failure signs and symptoms and renal function in  subjects with acute heart failure syndrome and renal impairment who are hospitalized for  volume overload and require intravenous diuretic therapy. 
  • Spirit Small Vessel Study – Closed: Clinical evaluation of the 2.25 mm XIENCE ™ V Everolimus Eluting Coronary Stent. 
  • Enlighten Il – Guidant- Closed 
  • OASIS-5- Closed 
  • Capture and Capture II (Carotid Stents)- Closed

Sub Investigator

  • Empact MI– (Started 4/9/2021- Present). A streamlined, multicentre, randomised, parallel group, double-blind placebo-controlled  superiority trial to evaluate the effect of EMPAgliflozin on hospitalisation for heart failure and  mortality in patients with aCuTe Myocardial Infarction 
  • Precision HTN – (Started 12/10/2020- Present). Multi-center, blinded, randomized, parallel-group, Phase 3 study with aprocitentan in  subjects with resistant hypertension (RHT).
  • Aegis 2 – (Started 8/29/2018 to present). A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group  Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary  Syndrome
  • Esperion- Clear Outcomes- (Started 2/15/2018 to Present). A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of  Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in  Patients with, or at high risk for, Cardiovascular Disease who are Statin Intolerant.
  • Esperion- Clear Serenity- (Started 2/28/2017 to 5/9/2018). A Randomized, Double-Blind, Parallel Group, Multicenter study to evaluate the efficacy  and safety of Bempedoic Acid (ETC-1002) 180 MG compared to placebo added to  background lipid modifying therapy in patients with elevated LDL-C who are statin  intolerant
  • HEART-FID- (Started 6/2017- to Present). A Randomized, Double Blind, Placebo Controlled Study to Investigate the Efficacy and  Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with  Iron Deficiency.
  • MERCK-(Victoria) – (Started 12/12/2016 to 11/20/2019). A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC  Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) – VerICiguaT Global Study in Subjects With Heart Failure With Reduced  ejection Fraction (VICTORIA)
  • DALCOR 301 – (Started 7/18/2016 Closed 4/4/2017). A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of  dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent  Acute Coronary Syndrome (ACS): The dal-GenE trial.
  • CSL112_2001 – (Started 6/13/2016 to 9/2017). A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group,  Study to Investigate the Safety and Tolerability of Multiple Dose Administration of  CSL112 in Subjects with Moderate Renal Impairment and Acute Myocardial Infarction
  • MARINER: (10/2014 to 2017) – Medically Ill Patient Assessment of Rivaroxaban versus Placebo IN Reducing Post Discharge Venous Thrombo-Embolism Risk. The primary objective is to assess the  efficacy and safety of rivaroxaban compared with placebo in the prevention of  symptomatic venous thromboembolism (VTE: lower extremity deep vein thrombosis  [DVT] and non-fatal pulmonary embolism [PE]) and VTE-related death post-hospital  discharge in high risk, medically ill patients.
  • Amgen Glagov – (8/31/2013 to 11/2016). A Double-Blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to  Determine the Effects of Evolocumab (AMG 145) Treatment on Atherosclerotic Disease  Burden as Measured by Intravascular Ultrasound in Subjects undergoing Coronary  Catheterization. 
  • AMGEN OLE – (07/2015 to 7/05/2018) A Multicenter, Open-label Extension (OLE) Study to Assess the Long-term Safety and  Efficacy of Evolocumab.
  • AEGIS 1: (Started 03/11/15 Closed 10/05/16). A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to  Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in  Subjects with Acute Myocardial Infarction
  • Odyssey Outcomes: (09/2014 to 11/2017) – A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the  Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients  Who Have Recently Experienced an Acute Coronary Syndrome
  • Gemini – (2015-11/2016). A Randomized, Double-blind, Double-dummy, Active-controlled, Parallel group,  Multicenter Study to Compare the Safety of Rivaroxaban versus Acetylsalicylic Acid in  Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects with Acute Coronary  Syndrome
  • Reveal In Office 2 (RIO2): 05/21/15 to 05/19/16 – Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States The primary purpose  of the RIO 2 study is to demonstrate that the Reveal LINQ™ procedure performed in the  in-office setting is as safe as LINQ™ insertions performed in the traditional hospital  setting (operating room, cardiac catheterization or electrophysiology (EP) laboratory).  The RIO 2 study also provides the opportunity to evaluate the economic value of in office Reveal LINQ™ insertions by characterizing the LINQ™ procedure time and  resources required to facilitate the procedure in the in-office and hospital settings. 
  • WRAP-IT: 04/28/15 to present – Medtronic, Inc. is sponsoring the World-wide Randomized Antibiotic EnveloPe Infection  PrevenTion Trial (WRAP-IT), a randomized, prospective, multi-center, single blinded,  post-market, interventional clinical study. The study has three purposes. First, the  WRAP-IT study will serve as a post-approval study for those geographies requiring a  post-approval study to facilitate collection of complications related to the Cardiovascular  Implantable Electronic Device (CIED) procedure or system in subjects randomized to  receive the TYRXTM Absorbable Antibacterial Envelope (henceforth referred to as  TYRX envelope). Next, this study will evaluate the ability of the TYRX envelope to  reduce major CIED infections through 12-months post-procedure following CIED  generator replacement, upgrade, revision, or the implant of a de novo CRT-D. Finally  this large device study provides the unique opportunity to prospectively characterize the  performance of Medtronic’s lead monitoring features in subjects whose CIED system  includes a transvenous RV defibrillation lead. 
  • AMPLIFY – Closed. To determine if at least one of the apixaban regimens is superior to placebo in the  combined endpoint of symptomatic, recurrent VTE (DVT or non-fatal PE) or all-cause  death in subjects who have an objectively documented index event of symptomatic  proximal DVT or symptomatic PE, have completed approximately 6 to 12 months of  standard anticoagulant therapy for the treatment of the index event, and have no  objectively documented recurrence of VTE after the index event.
  • Aristotle – Closed. To determine if Apixiban is non-inferior to warfarin (INR target range 2.0 to 3.0) in the  combined endpoint of stroke (ischemic or hemorrhagic) and systemic embolism in  subjects with atrial fibrillation and at least one additional risk factor for stroke.
  • Ascend HF – Closed. Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of  Nesiritide in Subjects With Decompensated Heart Failure.
  • ATLAS II – Closed. Evaluates safety and efficacy of rivaroxaban in subjects with a recent acute coronary  syndrome.
  • Avante Garde TIMI 43 – Closed. A randomized, double-blind, parallel-group, placebo-controlled, multinational clinical trial  to evaluate the efficacy of aliskiren and valsartan versus placebo in lowering levels on  NT-proBNP in stabilized patients post acute coronary syndromes.
  • BALANCE – Closed. To demonstrate that lixivaptan is a safe and effective agent for achieving and  maintaining increased serum sodium concentrations in patients with congestive heart  failure (CHF).
  • Borealis – Closed. To evaluate whether once weekly subcutaneous (s.c.) injection of biotinylated  idraparinux is at least as effective as oral International Normalized Ratio (INR) adjusted dose Warfarin in the prevention of stroke or systemic embolic event in patients with atrial fibrillation.
  • Champion – Closed. A clinical trial comparing cangrelor to clopidogrel in subjects who require percutaneous  coronary intervention.
  • Cordis ELITE – Closed. Compares the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting  Stent Systems.
  • Current (Oasis 7) – Closed. Clopidogrel optimal loading dose Usage to Reduce Recurrent EveNTs.
  • Eminence – Closed. A randomized, multi-center, open-label, parallel group feasibility study to determine the  safety and efficacy of the rationally engineered heparin M118 vs UFH in patient with  stable coronary artery disease undergoing percutaneous coronary intervention.
  • Improve-It – Closed. A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and  Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High Risk Subjects Presenting with Acute Coronary Syndrome (IMProved Reduction of  Outcomes: Vytorin Efficacy International Trial).
  • Innovate – Closed. Evaluates the clinical efficacy, safety, and tolerability of IV and oral PRT060128 in  patients undergoing non-urgent Percutaneous Coronary Intervention (PCI).
  • Plato – Closed. D5130C05262 – A Randomized, Double-blind, Parallel Group, Phase 3, Efficacy and  Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events  in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS).
  • SAPPHIRE – Closed. Stenting and angioplasty with protection in patients at high risk for endarterectomy.
  • SATURN – Closed. Compares the effects of rosuvastin 40 mg with atrovastatin 80 mg on the percent  atheroma volume (PAV) of a coronary artery as measured by intravascular ultrasound  (IVUS) imaging following104 weeks of treatment in patients with coronary artery disease  (CAD).
  • Sepia ACS – Closed. A Randomized, double-blind, triple-dummy, dose-ranging study, including an active  control of unfractionated heparin and eptifibatide, to evaluate the clinical efficacy and  safety of otamixaban, in patients with non-ST elevation acute coronary syndrome and  planned early invasive strategy.
  • Stability – Closed. Compares the chronic effects of Darapladib EC tablets, 160 mg versus placebo, when  added to the standard of care, on the incidence of major adverse cardiovascular events  (MACE) in high risk patients with chronic CHD.
  • TRA 2P – Closed. To evaluate the safety and efficacy of SCH 530348 in addition to standard of care in  subjects with a history of atherosclerotic disease.
  • TRA*CER – Closed. To evaluate the safety and efficacy of SCH530348; addition to standard of care in  patients with acute coronary syndrome.
  • Trilogy – Closed. A comparison of prasugrel and clopidogrel in acute coronary syndrome (ACS) patients  with unstable anginalnon-ST elevation myocardial infarction (UAINSTEMI) who are  medically managed.
  • XIENCE – Post approval study of the XIENCE™ V Everolimus Eluting Coronary Stent System  (EECSS).

Services Offered: AHI & TCC

Preventive Cardiology:

Coronary Artery Disease:

  • Percutaneous Coronary Revascularization:
      • Minimally Invasive Stent Insertion (pioneering radial intervention since 1997)
      • Laser Atherectomy.
      • Directional Coronary Atherectomy, simple and complex lesions. (pioneered in  Amarillo)
      • Transluminal Extraction Atherectomy-Native Arteries and Grafts, Percutaneous Transluminal Rotational Atherectomy. (Pioneered in Amarillo).  
      • Diagnostic Intravascular Ultrasound. (pioneered in Amarillo)

Peripheral Arterial Disease:

Venous Disease:

Valvular Heart Disease:

Stroke and TIA Management:

Congestive Heart failure:

  • Systolic and DiastolicEarly, Chronic and Advanced.
  • Medical Management
  • Left Ventricular support